Research Topics
| James W DenhamSummaryAffiliation: University of Newcastle Country: Australia Publications
| Collaborators
|
Detail Information
Publications
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancerJames W Denham
University of Newcastle, Australia
Radiother Oncol 105:184-92. 2012..This study examines whether these measures increase rectal and urinary dysfunction and are secondary trial endpoints...- Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trialJames W Denham
School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
Lancet Oncol 13:1260-70. 2012..In this study, we investigated whether these treatments had a detrimental effect on patient-reported-outcome (PRO) scores... 
Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trialDaniel A Galvão
Edith Cowan University Health and Wellness Institute and School of Exercise and Health Sciences, Edith Cowan University, Joondalup, Australia
BMC Cancer 11:517. 2011..The aim of this study is to determine the efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases...- A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trialDaniel A Galvão
Vario Health Institute, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
BMC Cancer 9:419. 2009..Our primary outcomes are cardiorespiratory capacity, abdominal obesity, and lipid and glycemic control, while secondary outcomes include self-reported physical activity, quality of life and psychological distress... - Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?James W Denham
School of Medicine and Public Health, University of Newcastle, New South Wales, Australia
Int J Radiat Oncol Biol Phys 75:1008-12. 2009..We sought to determine whether short-term neoadjuvant androgen deprivation (STAD) duration influences the optimal time point from which Phoenix fail (time to biochemical failure; TTBF) should be measured... - Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancerJames W Denham
University of Newcastle, New South Wales, Australia
Int J Radiat Oncol Biol Phys 74:404-11. 2009..We studied prostate-specific antigen (PSA) changes after radiation with or without neoadjuvant androgen deprivation to determine posttreatment PSA scenarios in which false-positive biochemical failures (FPBF) are most likely to occur... 
It's time to depolarise the unhelpful PSA-testing debate and put into practice lessons from the two major international screening trialsJames W Denham
Prostate Cancer Trials Group, University of Newcastle, Newcastle, NSW, Australia
Med J Aust 192:393-6. 2010..quot;Active surveillance" programs (whereby men with early-stage cancers are monitored regularly by PSA testing and digital rectal examinations) and development of counselling services should be encouraged...- PSA response signatures - a powerful new prognostic indicator after radiation for prostate cancer?James W Denham
University of Newcastle, NSW, Australia
Radiother Oncol 90:382-8. 2009..We sought to determine whether inter-patient variations in pattern of PSA changes after radiation exist and, if so, are they prognostically significant... - Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?James W Denham
School of Medicine and Public Health, The University of Newcastle, Newcastle, New South Wales, Australia
Cancer 115:4477-87. 2009..The authors sought to determine why using randomized trial data with 7-year minimum follow-up... - Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham
School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
Lancet Oncol 12:451-9. 2011..Here we report the 10-year results... - Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trialJames W Denham
Newcastle Mater Hospital, Newcastle, New South Wales, Australia
Lancet Oncol 6:841-50. 2005..We did a large randomised controlled trial to determine whether 3 months or 6 months of androgen deprivation given before and during radiotherapy improves outcomes for patients with locally advanced prostate cancer... - Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trialJames W Denham
School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia
Lancet Oncol 9:1058-68. 2008..We sought to assess time to biochemical failure (TTBF) and prostate-specific antigen doubling time (PSADT) after failure of curative treatment as candidates for this endpoint... - Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trialAnne Capp
Calvary Mater Newcastle, NSW, Australia
Radiother Oncol 90:400-7. 2009..We sought to categorize longitudinal radiation-induced rectal toxicity data obtained from men participating in a randomised controlled trial for locally advanced prostate cancer... - Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler
School of Medicine and Public Health, The University of Newcastle, University Drive, Callaghan, NSW 2308, Australia
Prostate Cancer 2012:814724. 2012..External validation, particularly in long-term AST and radiotherapy datasets, is necessary... - Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancerPeter C O'Brien
Department of Radiation Oncology, Newcastle Mater Hospital, Waratah, NSW, Australia
Int J Radiat Oncol Biol Phys 58:75-80. 2004..To describe the natural history of mucosal changes, in particular the development of telangiectases in the rectum, after radiotherapy (RT) for prostate cancer... - Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long termChantelle Wilcox
School of Medicine and Public Health, The University of Newcastle, Callaghan, N S W, Australia
Oncology 82:56-8. 2012..To determine if 6 months of neo-adjuvant androgen deprivation is associated with the long-term risk of cardiac mortality... - A magnetic resonance imaging-based workflow for planning radiation therapy for prostate cancerPeter B Greer
Calvary Mater Newcastle Hospital, Newcastle, NSW, Australia
Med J Aust 194:S24-7. 2011..MRI-based radiotherapy planning can also be used for tumours in other locations, such as head and neck, and breast cancers... - Treatment-related morbidity in prostate cancer: a comparison of 3-dimensional conformal radiation therapy with and without image guidance using implanted fiducial markersJasmeet Singh
Calvary Mater Newcastle, Newcastle, Australia
Int J Radiat Oncol Biol Phys 85:1018-23. 2013..To estimate the prevalence of rectal and urinary dysfunctional symptoms using image guided radiation therapy (IGRT) with fiducials and magnetic resonance planning for prostate cancer... - Thrombin generation as a predictor of radiotherapy induced skin erythemaLisa F Lincz
Department of Haematology, Calvary Mater Newcastle, NSW, Australia
Radiother Oncol 90:136-40. 2009..Based on the recent findings in patients suffering from chronic urticaria, we sought to determine if similar mechanisms of hypercoagulation contributed to comparable skin reactions during radiotherapy... - Breast edema in patients undergoing breast-conserving treatment for breast cancer: assessment via high frequency ultrasoundChristopher R Wratten
Radiation Oncology, Newcastle Mater Hospital, Waratah, NSW, Australia
Breast J 13:266-73. 2007..HFUS appears to be a useful in the research setting in quantifying the effect of techniques that aim to reduce complications such as edema... - 'When measurements mean action' decision models for portal image review to eliminate systematic set-up errorsChristopher R Wratten
Radiation Oncology, Newcastle Mater Hospital, Newcastle, New South Wales, Australia
Australas Radiol 48:272-9. 2004..When combined with the potential for rapid diagnosis of larger (>4 mm) systematic errors using one-dimensional decision models, HEP can eliminate the majority of systematic errors during the first 2 treatment weeks... - MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planningJonathan Lambert
School of Mathematical and Physical Sciences, University of Newcastle, University Drive, Callaghan, NSW 2308, Australia
Radiother Oncol 98:330-4. 2011..This study compares the accuracy of MR-alone based dose calculations with bulk electron density assignment to CT-based dose calculations for prostate radiotherapy... - Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology GroupPeter C O'Brien
Department of Radiation Oncology, Newcastle Mater Hospital, Newcastle, NSW, Australia
Int J Radiat Oncol Biol Phys 54:442-9. 2002.... - The radiotherapeutic injury--a complex 'wound'James W Denham
Department of Radiation Oncology, Newcastle Mater Misericordiae Hospital, Newcastle University, Locked Bag 7, Hunter Region Mail Centre, NSW 2310, Newcastle, Australia
Radiother Oncol 63:129-45. 2002..Important clinical implications relevant to these processes are also discussed...